Home › Myasthenia Gravis › Connecticut › New Haven
Myasthenia Gravis clinical trials in New Haven, CT
4 studies for Myasthenia Gravis are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RecruitingPhase 3
- Site Number - 1001, New Haven
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RecruitingPhase 3
- Yale New Haven Hospital, New Haven
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
RecruitingObservational study
- Clinical Trial Site, New Haven
The EXPLORE MG Registry for Myasthenia Gravis
RecruitingObservational study
- Yale-New Haven Hospital, New Haven
About Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
More about Myasthenia Gravis on MedlinePlus
Myasthenia Gravis trials in other cities
- Tampa, FL12 studies
- Houston, TX11 studies
- Durham, NC10 studies
- Boca Raton, FL10 studies
- Columbus, OH8 studies
- Milwaukee, WI7 studies
- St. Louis, MO7 studies
- New York City, NY7 studies
- Miami, FL7 studies
- Dallas, TX6 studies
- Jacksonville, FL6 studies
- Orange, CA6 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Colorectal Cancer20 studies
- Prostate Cancer20 studies
- Opioid Overdose18 studies
- Alcohol Use Disorder (AUD)17 studies
- Acute Myeloid Leukemia17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.